Neuronetics (STIM) Stock
Medical device maker for brain stimulation therapy. Here's the price, business snapshot, and what's worth knowing about Neuronetics in August 2026.
Neuronetics Inc (ticker STIM) is a medical‑device company that develops and commercialises non‑invasive neurostimulation systems. Its flagship product, the NeuroStar Transcranial Magnetic Stimulation (TMS) System, is used primarily to treat major depressive disorder and related indications. The company earns revenue from device sales, clinical consumables, service contracts, training and, in some markets, clinic partnerships or leasing arrangements. With a market capitalisation of roughly $190.4m, Neuronetics is a small‑cap healthcare business: potential upside includes broader clinical adoption, expanded regulatory approvals and improved reimbursement, while risks include limited product diversification, competitive neuromodulation technologies, reimbursement uncertainty and the regulatory and commercial hurdles common to medical‑device firms. Investors should note small‑cap volatility and that past performance does not predict future returns. This content is general educational information only and not personal financial advice; suitability depends on an investor’s objectives and risk tolerance and you may wish to seek independent advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying NeuroMetics' stock with a target price of $6.50, indicating strong growth potential.
Financial Health
Neuronetics is showing strong sales, reasonable cash flow, and a solid profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Adoption & Growth
Broader clinical adoption and better reimbursement could lift sales, though uptake varies by region and payer coverage and performance can differ.
Innovation Programme
Ongoing clinical studies aim to expand indications and improve outcomes; technical progress and regulatory approvals will shape future prospects.
Market & Competition
Competes with other neuromodulation technologies and pharmacological treatments; reimbursement and competitor advances are important risks to monitor.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
